ClinConnect ClinConnect Logo
Search / Trial NCT06778096

Transdiagnostic Internet Cognitive-behavior Therapy for Mixed Anxiety and Depressive Symptoms in Postnatal Women

Launched by UNIVERSITÉ DE SHERBROOKE · Jan 10, 2025

Trial Information

Current as of May 03, 2025

Not yet recruiting

Keywords

Cognitive Behavioral Therapy Internet Non Guided Transdiagnostic Randomized Clinical Trial Anxiety Depression Postnatal

ClinConnect Summary

This clinical trial is looking at a new online therapy program designed to help women who are experiencing anxiety and depression after giving birth. The program is called Internet Cognitive Behavioral Therapy (iCBT), and the researchers want to find out if adding this program to the usual care women receive can help reduce their symptoms more effectively than just the usual care alone. Participants will be women who are within 12 months of giving birth and are fluent in French. They will need to have a certain level of anxiety or depression, as determined by a couple of questionnaires.

Women who join the study will either take part in the iCBT program for six weeks or be placed in a waitlist group where they will receive the usual care and then access the iCBT after the study period. All participants will fill out questionnaires at the start of the trial, after six weeks, and then again four weeks later to help the researchers understand how well the program works. It's important to note that women with certain conditions, like severe depression or those currently using specific medications, won't be eligible for this study.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • 18 years and older
  • Being within 12 months postpartum
  • Fluent in spoken and written French
  • Self-reported clinical score ≥10 for anxiety and/or depressive symptoms based on the Generalised Anxiety Disorder-7 (GAD-7) and the Edinburgh Postnatal Depression Scale 10-item scale (EPDS)
  • Access to a computer/tablet and internet connection
  • Agreement to share primary provider contact information
  • Exclusion Criteria:
  • Self-reported diagnosis of schizophrenia or bipolar disorder
  • Current substance abuse or dependence
  • Current use of benzodiazepines
  • Beginning psychological therapy (\< 4 weeks ago) or medication (\< 8 weeks ago) for depression/anxiety
  • Severe depression (EPDS score ≥ 23) or active suicidal intentions (EPDS question 10 = 3, yes quite often)

About Université De Sherbrooke

The Université de Sherbrooke is a leading research institution in Canada, renowned for its commitment to advancing knowledge and innovation in various fields, including health sciences. With a focus on interdisciplinary collaboration, the university actively engages in clinical trials to explore new therapeutic interventions and improve patient care. Its research team comprises experienced professionals dedicated to ensuring the highest ethical standards and scientific rigor in clinical research. The Université de Sherbrooke strives to translate research findings into practical solutions that enhance health outcomes and contribute to the advancement of medical science.

Locations

Ottawa, Ontario, Canada

Châteauguay, Quebec, Canada

Greenfield Park, Quebec, Canada

Longueuil, Quebec, Canada

Sherbrooke, Quebec, Canada

Patients applied

0 patients applied

Trial Officials

Pasquale Roberge, PhD

Principal Investigator

Université de Sherbrooke

Helen-Maria Vasiliadis, PhD

Principal Investigator

Université de Sherbrooke

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported